Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371.

View in: PubMed

subject areas

Aged
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Female
Humans
Ki-67 Antigen
Middle Aged
Neoadjuvant Therapy
Nitriles
Postmenopause
Receptor, ErbB-2
Receptors, Estrogen
Triazoles
Triple Negative Breast Neoplasms

authors with profiles

Olwen Hahn